Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.65
LXRX's Cash to Debt is ranked lower than
65% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. LXRX: 4.65 )
Ranked among companies with meaningful Cash to Debt only.
LXRX' s Cash to Debt Range Over the Past 10 Years
Min: 1.31  Med: 5.18 Max: No Debt
Current: 4.65
Equity to Asset 0.41
LXRX's Equity to Asset is ranked lower than
77% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. LXRX: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
LXRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.64 Max: 0.96
Current: 0.41
0.33
0.96
F-Score: 5
Z-Score: 1.05
M-Score: 1.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.18
LXRX's Operating margin (%) is ranked higher than
68% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. LXRX: -4.18 )
Ranked among companies with meaningful Operating margin (%) only.
LXRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: -4.18
-9955.46
1.13
Net-margin (%) -8.16
LXRX's Net-margin (%) is ranked higher than
66% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. LXRX: -8.16 )
Ranked among companies with meaningful Net-margin (%) only.
LXRX' s Net-margin (%) Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -8.16
-10120.39
-3.6
ROE (%) -4.69
LXRX's ROE (%) is ranked higher than
72% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. LXRX: -4.69 )
Ranked among companies with meaningful ROE (%) only.
LXRX' s ROE (%) Range Over the Past 10 Years
Min: -63.41  Med: -43.42 Max: -1.64
Current: -4.69
-63.41
-1.64
ROA (%) -2.28
LXRX's ROA (%) is ranked higher than
74% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. LXRX: -2.28 )
Ranked among companies with meaningful ROA (%) only.
LXRX' s ROA (%) Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -2.28
-32.59
-0.83
ROC (Joel Greenblatt) (%) -46.18
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. LXRX: -46.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LXRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -414.95  Med: -161.37 Max: 70.58
Current: -46.18
-414.95
70.58
Revenue Growth (3Y)(%) 328.10
LXRX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. LXRX: 328.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LXRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.6  Med: -27.75 Max: 328.1
Current: 328.1
-71.6
328.1
EPS Growth (3Y)(%) -68.60
LXRX's EPS Growth (3Y)(%) is ranked lower than
97% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. LXRX: -68.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LXRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.6  Med: -13.20 Max: 29.1
Current: -68.6
-68.6
29.1
» LXRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

LXRX Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 14,285 sh (-86.42%)
Chuck Royce 377,074 sh (-86.60%)
Jim Simons 170,153 sh (-89.60%)
» More
Q3 2015

LXRX Guru Trades in Q3 2015

Paul Tudor Jones 15,299 sh (New)
Mario Gabelli 14,285 sh (unchged)
Chuck Royce 334,374 sh (-11.32%)
Jim Simons 11,086 sh (-93.48%)
» More
Q4 2015

LXRX Guru Trades in Q4 2015

Mario Gabelli 16,100 sh (+12.71%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 259,589 sh (-22.37%)
» More
Q1 2016

LXRX Guru Trades in Q1 2016

Joel Greenblatt 189,317 sh (New)
Chuck Royce 340,589 sh (+31.20%)
Mario Gabelli 16,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:AKABY, NAS:AGIO, NAS:DBVT, NAS:ARIA, NAS:ONCE, NAS:ITCI, NAS:BLUE, NAS:PRTA, NAS:RLYP, NYSE:CBM, OTCPK:GENSF, NAS:SAGE, NYSE:AXON, OTCPK:PFSCF, NAS:PTLA, NAS:MCRB, NAS:ALDR, NAS:INVA, NYSE:PBYI, OTCPK:SXMDF » details
Traded in other countries:LX31.Germany,
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.

Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 11.39
LXRX's Price/Owner Earnings (ttm) is ranked higher than
83% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. LXRX: 11.39 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LXRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.41  Med: 10.24 Max: 27.88
Current: 11.39
5.41
27.88
P/B 6.73
LXRX's P/B is ranked lower than
74% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. LXRX: 6.73 )
Ranked among companies with meaningful P/B only.
LXRX' s P/B Range Over the Past 10 Years
Min: 0.66  Med: 3.12 Max: 10.19
Current: 6.73
0.66
10.19
P/S 11.96
LXRX's P/S is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. LXRX: 11.96 )
Ranked among companies with meaningful P/S only.
LXRX' s P/S Range Over the Past 10 Years
Min: 2.62  Med: 24.28 Max: 1440
Current: 11.96
2.62
1440
PFCF 10.32
LXRX's PFCF is ranked higher than
81% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. LXRX: 10.32 )
Ranked among companies with meaningful PFCF only.
LXRX' s PFCF Range Over the Past 10 Years
Min: 4.92  Med: 9.23 Max: 22.78
Current: 10.32
4.92
22.78
POCF 10.27
LXRX's POCF is ranked higher than
80% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. LXRX: 10.27 )
Ranked among companies with meaningful POCF only.
LXRX' s POCF Range Over the Past 10 Years
Min: 4.9  Med: 10.31 Max: 45.01
Current: 10.27
4.9
45.01
Current Ratio 4.04
LXRX's Current Ratio is ranked lower than
54% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. LXRX: 4.04 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.75 Max: 31.11
Current: 4.04
0.95
31.11
Quick Ratio 4.04
LXRX's Quick Ratio is ranked lower than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. LXRX: 4.04 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.75 Max: 31.11
Current: 4.04
0.95
31.11
Days Sales Outstanding 1.92
LXRX's Days Sales Outstanding is ranked higher than
96% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. LXRX: 1.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.56  Med: 22.17 Max: 461.86
Current: 1.92
2.56
461.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.32
LXRX's Price/Net Cash is ranked lower than
78% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. LXRX: 14.32 )
Ranked among companies with meaningful Price/Net Cash only.
LXRX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.17  Med: 7.05 Max: 92.26
Current: 14.32
1.17
92.26
Price/Net Current Asset Value 12.65
LXRX's Price/Net Current Asset Value is ranked lower than
78% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. LXRX: 12.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LXRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.13  Med: 5.76 Max: 302.75
Current: 12.65
1.13
302.75
Price/Tangible Book 10.95
LXRX's Price/Tangible Book is ranked lower than
80% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. LXRX: 10.95 )
Ranked among companies with meaningful Price/Tangible Book only.
LXRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.89  Med: 4.01 Max: 44.55
Current: 10.95
0.89
44.55
Price/Median PS Value 0.49
LXRX's Price/Median PS Value is ranked higher than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. LXRX: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
LXRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.57 Max: 49
Current: 0.49
0.11
49
Earnings Yield (Greenblatt) (%) -0.36
LXRX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. LXRX: -0.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LXRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.4  Med: 20.10 Max: 1944.4
Current: -0.36
-0.4
1944.4

More Statistics

Revenue (TTM) (Mil) $140.7
EPS (TTM) $ -0.12
Beta-0.19
Short Percentage of Float48.71%
52-Week Range $7.65 - 16.98
Shares Outstanding (Mil)103.85

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 98 91 128
EPS ($) -1.21 -1.32 -0.80
EPS w/o NRI ($) -1.21 -1.32 -0.80
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization... Jul 18 2016
Lexicon to Present at the Cantor Fitzgerald Healthcare Conference Jul 07 2016
Lexicon To Present At The Cantor Fitzgerald Healthcare Conference Jul 07 2016
Frank Palantoni joins Laboratoire M2 as CEO Jun 22 2016
ETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 21, 2016 Jun 21 2016
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US :... Jun 20 2016
ETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 9, 2016 Jun 09 2016
Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Jun 08 2016
Lexicon to Present at the Jefferies 2016 Healthcare Conference Jun 06 2016
Lexicon To Present At The Jefferies 2016 Healthcare Conference Jun 06 2016
Premarket Research Report Covering the Biotech Industry Jun 06 2016
Lexicon Announces the Launch of AboutCarcinoid.com to Provide Carcinoid Syndrome Disease Education... Jun 02 2016
Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education... Jun 02 2016
Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the... May 31 2016
Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The... May 31 2016
Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : May 27, 2016 May 26 2016
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : May... May 24 2016
7 Stocks Spiking on Big Volume May 24 2016
LEXICON PHARMACEUTICALS, INC. Financials May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)